Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende
Erweiterte Suche
Anmelden
nach oben
CNS Drugs
Erschienen in: CNS Drugs 6/2015

01.06.2015 | Current Opinion

Targeting CGRP: A New Era for Migraine Treatment

verfasst von: Stephanie Wrobel Goldberg, Stephen David Silberstein

Erschienen in: CNS Drugs | Ausgabe 6/2015

Einloggen, um Zugang zu erhalten

Abstract

Migraine is a highly prevalent headache disease that typically affects patients during their most productive years. Despite significant progress in understanding the underlying pathophysiology of this disorder, its treatment so far continues to depend on drugs that, in their majority, were not specifically designed for this purpose. The neuropeptide calcitonin gene-related peptide (CGRP) has been indicated as playing a critical role in the central and peripheral pathways leading to a migraine attack. It is not surprising that drugs designed to specifically block its action are gaining remarkable attention from researchers in the field with, at least so far, a safe risk profile. In this article, we highlight the evolution from older traditional treatments to the innovative CGRP target drugs that are revolutionizing the way to approach this debilitating neurological disease. We provide a brief introduction on pathophysiology of migraine and details on the characteristic, function, and localization of CGRP to then focus on CGRP receptor antagonists (CGRP-RAs) and CGRP monoclonal antibodies (CGRP mAbs).
Literatur
1.
Murray CJ, Vos T, Lozano R, et al. Disability-adjusted life years (DALYs) for 291 diseases and injuries in 21 regions, 1990–2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet. 2012;380:2197–223.PubMedCrossRef
2.
Stewart WF, Lipton RB, Celentano DD, Reed ML. Prevalence of migraine headache in the United States. Relation to age, income, race and other sociodemographic factors. JAMA. 1992;267:64–9.PubMedCrossRef
3.
Headache Classification Committee of the International Headache Society (IHS). The international classification of headache disorders, 3rd edition (beta version). Cephalalgia 2013;33:629–808.CrossRef
4.
5.
Schulman EA, Dermott KF. Sumatriptan plus metoclopramide in triptan-nonresponsive migraineurs. Headache. 2003;43:729–33.PubMedCrossRef
6.
Papademetriou V. Cardiovascular risk assessment and triptans. Headache. 2004;44(Suppl 1):S31–9.PubMedCrossRef
7.
Goadsby PJ, Lipton RB, Ferrari MD. Migraine-current understanding and treatment. N Engl J Med. 2002;346:257–70.PubMedCrossRef
8.
9.
Goadsby PJ. Therapeutic prospects for migraine: can paradise be regained? Ann Neurol. 2013;74:423–34.PubMedCrossRef
10.
Bigal ME, Walter S, Rapoport AM. Therapeutic antibodies against CGRP or its receptor. Br J Clin Pharmacol. 2015;79:886–95.PubMedCrossRef
11.
Silberstein SD, Holland S, Freitag F, Dodick DW, Argoff C, Ashman E. Evidence-based guideline update: pharmacologic treatment for episodic migraine prevention in adults: report of the Quality Standards Subcommittee of the American Academy of Neurology and the American Headache Society. Neurology. 2012;78:1337–45.PubMedPubMedCentralCrossRef
12.
Martelletti P. The therapeutic armamentarium in migraine is quite elderly. Expert Opin Drug Metab Toxicol. 2015;11:175–7.PubMedCrossRef
13.
14.
Goadsby PJ, Silberstein SD, Dodick DW. Chronic daily headaches for clinicians. Hamilton: BC Decker Inc; 2005.
15.
Edvinsson L. Blockade of CGRP receptors in the intracranial vasculature: a new target in the treatment of headache. Cephalalgia. 2004;24:611–22.PubMedCrossRef
16.
Burstein R, Jakubowski M. Unitary hypothesis for multiple triggers of the pain and strain of migraine. J Comp Neurol. 2005;493:9–14.PubMedCrossRef
17.
Goadsby PJ, Zagami AS. Stimulation of the superior sagittal sinus increases metabolic activity and blood flow in certain regions of the brainstem and upper cervical spinal cord of the cat. Brain. 1991;114:1001–11.PubMedCrossRef
18.
Goadsby PJ, Zagami AS, Lambert GA. Neural processing of craniovascular pain: synthesis of the central structures involved in migraine. Headache. 1991;31:365–71.PubMedCrossRef
19.
Goadsby PJ, Hoskin KL, Knight YE. Stimulation of the greater occipital nerve increases metabolic activity in the trigeminal nucleus caudalis and cervical dorsal horn of the cat. Pain. 1997;73:23–8.PubMedCrossRef
20.
21.
Bigal ME, Walter S, Rapoport AM. The vasodilatory activity of CGRP: a response. Headache. 2014;54:748–9.PubMedCrossRef
22.
Goadsby PJ, Edvinsson L, Ekman R. Vasoactive peptide release in the extracerebral circulation of humans during migraine headache. Ann Neurol. 1990;28:183–7.PubMedCrossRef
23.
Arulmani U, MaassenVanDenBrink A, Villalon CM, Saxena PR. Calcitonin gene-related peptide and its role in migraine pathophysiology. Eur J Pharmacol. 2004;500:315–30.PubMedCrossRef
24.
Lassen LH, Haderslev PA, Jacobsen VB, Iversen HK, Sperling B, Olesen J. CGRP may play a causative role in migraine. Cephalalgia. 2002;22:54–61.PubMedCrossRef
25.
Hansen JM, Hauge AW, Olesen J, Ashina M. Calcitonin gene-related peptide triggers migraine-like attacks in patients with migraine with aura. Cephalalgia. 2010;30:1179–86.PubMedCrossRef
26.
Cady RK, Vause CV, Ho TW, Bigal ME, Durham PL. Elevated saliva calcitonin gene-related peptide levels during acute migraine predict therapeutic response to rizatriptan. Headache. 2009;49:1258–66.PubMedCrossRef
27.
Rosenfeld MG, Mermod JJ, Amara SG, et al. Production of a novel neuropeptide encoded by the calcitonin gene via tissue-specific RNA processing. Nature. 1983;304:129–35.PubMedCrossRef
28.
Poyner DR, Sexton PM, Marshall I, et al. International union of pharmacology. XXXII. The mammalian calcitonin gene-related peptides, adrenomedullin, amylin, and calcitonin receptors. Pharmacol Rev. 2002;54:233–46.PubMedCrossRef
29.
Lafont AG, Dufour S, Fouchereau-Peron M. Evolution of the CT/CGRP family: comparative study with new data from models of teleosts, the eel, and cephalopod molluscs, the cuttlefish and the nautilus. Gen Comp Endocrinol. 2007;153:155–69.PubMedCrossRef
30.
Rezaeian AH, Isokane T, Nishibori M, et al. alphaCGRP and betaCGRP transcript amount in mouse tissues of various developmental stages and their tissue expression sites. Brain Dev. 2009;31:682–93.PubMedCrossRef
31.
Conner AC, Hay DL, Howitt SG, et al. Interaction of calcitonin-gene-related peptide with its receptors. Biochem Soc Trans. 2002;30:451–5.PubMedCrossRef
32.
Sternini C. Enteric and visceral afferent CGRP neurons. Targets of innervation and differential expression patterns. Ann N Y Acad Sci. 1992;657:170–86.PubMedCrossRef
33.
van Rossum D, Hanisch UK, Quirion R. Neuroanatomical localization, pharmacological characterization and functions of CGRP, related peptides and their receptors. Neurosci Biobehav Rev. 1997;21:649–78.PubMedCrossRef
34.
35.
Edvinsson L, Nilsson E, Jansen-Olesen I. Inhibitory effect of BIBN4096BS, CGRP(8-37), a CGRP antibody and an RNA-Spiegelmer on CGRP induced vasodilatation in the perfused and non-perfused rat middle cerebral artery. Br J Pharmacol. 2007;150:633–40.PubMedPubMedCentralCrossRef
36.
Raddant AC, Russo AF. Calcitonin gene-related peptide in migraine: intersection of peripheral inflammation and central modulation. Expert Rev Mol Med. 2011;13:e36.PubMedPubMedCentralCrossRef
37.
Tschopp FA, Henke H, Petermann JB, et al. Calcitonin gene-related peptide and its binding sites in the human central nervous system and pituitary. Proc Natl Acad Sci USA. 1985;82:248–52.PubMedPubMedCentralCrossRef
38.
Wimalawansa SJ. Calcitonin gene-related peptide and its receptors: molecular genetics, physiology, pathophysiology, and therapeutic potentials. Endocr Rev. 1996;17:533–85.PubMedCrossRef
39.
Ho TW, Edvinsson L, Goadsby PJ. CGRP and its receptors provide new insights into migraine pathophysiology. Nat Rev Neurol. 2010;6:573–82.PubMedCrossRef
40.
Kawai Y, Takami K, Shiosaka S, et al. Topographic localization of calcitonin gene-related peptide in the rat brain: an immunohistochemical analysis. Neuroscience. 1985;15:747–63.PubMedCrossRef
41.
Skofitsch G, Jacobowitz DM. Quantitative distribution of calcitonin gene-related peptide in the rat central nervous system. Peptides. 1985;6:1069–73.PubMedCrossRef
42.
Eftekhari S, Salvatore CA, Gaspar RC, et al. Localization of CGRP receptor components, CGRP, and receptor binding sites in human and rhesus cerebellar cortex. Cerebellum. 2013;12:937–49.PubMedCrossRef
43.
Eftekhari S, Salvatore CA, Johansson S, Chen TB, Zeng Z, Edvinsson L. Localization of CGRP, CGRP receptor, PACAP and glutamate in trigeminal ganglion. Relation to the blood-brain barrier. Brain Res. 2015;1600:93–109.PubMedCrossRef
44.
Eftekhari S, Warfvinge K, Blixt FW, Edvinsson L. Differentiation of nerve fibers storing CGRP and CGRP receptors in the peripheral trigeminovascular system. J Pain. 2013;14:1289–303.PubMedCrossRef
45.
Eftekhari S, Edvinsson L. Calcitonin gene-related peptide (CGRP) and its receptor components in human and rat spinal trigeminal nucleus and spinal cord at C1-level. BMC Neurosci. 2011;12:112.PubMedPubMedCentralCrossRef
46.
Goodman EC, Iversen LL. Calcitonin gene-related peptide: novel neuropeptide. Life Sci. 1986;38:2169–78.PubMedCrossRef
47.
Yallampalli C, Chauhan M, Thota CS, Kondapaka S, Wimalawansa SJ. Calcitonin gene-related peptide in pregnancy and its emerging receptor heterogeneity. Trends Endocrinol Metab. 2002;13:263–9.PubMedCrossRef
48.
Powell KJ, Ma W, Sutak M, Doods H, Quirion R, Jhamandas K. Blockade and reversal of spinal morphine tolerance by peptide and non-peptide calcitonin gene-related peptide receptor antagonists. Br J Pharmacol. 2000;131:875–84.PubMedPubMedCentralCrossRef
49.
Oku R, Satoh M, Fujii N, Otaka A, Yajima H, Takagi H. Calcitonin gene-related peptide promotes mechanical nociception by potentiating release of substance P from the spinal dorsal horn in rats. Brain Res. 1987;403:350–4.PubMedCrossRef
50.
Marvizon JC, Perez OA, Song B, et al. Calcitonin receptor-like receptor and receptor activity modifying protein 1 in the rat dorsal horn: localization in glutamatergic presynaptic terminals containing opioids and adrenergic alpha2C receptors. Neuroscience. 2007;148:250–65.PubMedPubMedCentralCrossRef
51.
Seybold VS. The role of peptides in central sensitization. Handb Exp Pharmacol 2009;194:451–91.PubMedCrossRef
52.
Rossi SG, Dickerson IM, Rotundo RL. Localization of the calcitonin gene-related peptide receptor complex at the vertebrate neuromuscular junction and its role in regulating acetylcholinesterase expression. J Biol Chem. 2003;278:24994–5000.PubMedCrossRef
53.
Ottosson A, Edvinsson L. Release of histamine from dural mast cells by substance P and calcitonin gene-related peptide. Cephalalgia. 1997;17:166–74.PubMedCrossRef
54.
Messlinger K, Hanesch U, Kurosawa M, Pawlak M, Schmidt RF. Calcitonin gene related peptide released from dural nerve fibers mediates increase of meningeal blood flow in the rat. Can J Physiol Pharmacol. 1995;73:1020–4.PubMedCrossRef
55.
Strassman AM, Raymond SA, Burstein R. Sensitization of meningeal sensory neurons and the origin of headaches. Nature. 1996;384:560–4.PubMedCrossRef
56.
Thalakoti S, Patil VV, Damodaram S, et al. Neuron-glia signaling in trigeminal ganglion: implications for migraine pathology. Headache. 2007;47:1008–23.PubMedPubMedCentralCrossRef
57.
Recober A, Kuburas A, Zhang Z, Wemmie JA, Anderson MG, Russo AF. Role of calcitonin gene-related peptide in light-aversive behavior: implications for migraine. J Neurosci. 2009;29:8798–804.PubMedPubMedCentralCrossRef
58.
Hay DL, Poyner DR, Quirion R. International Union of Pharmacology. LXIX. Status of the calcitonin gene-related peptide subtype 2 receptor. Pharmacol Rev. 2008;60:143–5.PubMedCrossRef
59.
Lin HY, Harris TL, Flannery MS, et al. Expression cloning of an adenylate cyclase-coupled calcitonin receptor. Science. 1991;254:1022–4.PubMedCrossRef
60.
Walker CS, Conner AC, Poyner DR, Hay DL. Regulation of signal transduction by calcitonin gene-related peptide receptors. Trends Pharmacol Sci. 2010;31:476–83.PubMedCrossRef
61.
ter Haar E, Koth CM, Abdul-Manan N, et al. Crystal structure of the ectodomain complex of the CGRP receptor, a class-B GPCR, reveals the site of drug antagonism. Structure. 2010;18:1083–93.PubMedCrossRef
62.
Kusano S, Kukimoto-Niino M, Akasaka R, et al. Crystal structure of the human receptor activity-modifying protein 1 extracellular domain. Protein Sci. 2008;17:1907–14.PubMedPubMedCentralCrossRef
63.
Foord SM, Marshall FH. RAMPs: accessory proteins for seven transmembrane domain receptors. Trends Pharmacol Sci. 1999;20:184–7.PubMedCrossRef
64.
Zhang Z, Winborn CS, de Marquez PB, Russo AF. Sensitization of calcitonin gene-related peptide receptors by receptor activity-modifying protein-1 in the trigeminal ganglion. J Neurosci. 2007;27:2693–703.PubMedCrossRef
65.
Walker CS, Hay DL. CGRP in the trigeminovascular system: a role for CGRP, adrenomedullin and amylin receptors? Br J Pharmacol. 2013;170:1293–307.PubMedPubMedCentralCrossRef
66.
Petersen KA, Birk S, Kitamura K, Olesen J. Effect of adrenomedullin on the cerebral circulation: relevance to primary headache disorders. Cephalalgia. 2009;29:23–30.PubMedCrossRef
67.
Walker CS, Eftekhari S, Bower RL, et al. A second trigeminal CGRP receptor; function and expression of the AMY1 receptor. Ann Clin Translational Neurol. 2015. doi:10.​1002/​acn3.​197.
68.
Bailey RJ, Walker CS, Ferner AH, et al. Pharmacological characterization of rat amylin receptors: implications for the identification of amylin receptor subtypes. Br J Pharmacol. 2012;166:151–67.PubMedPubMedCentralCrossRef
69.
Hay DL, Christopoulos G, Christopoulos A, Poyner DR, Sexton PM. Pharmacological discrimination of calcitonin receptor: receptor activity-modifying protein complexes. Mol Pharmacol. 2005;67:1655–65.PubMedCrossRef
70.
Hay DL, Eftekhari S, Bower RL, Wilderman A, Insel PA, Edvinsson L, Waldvogel HJ, Russo AF, Caron KM, and Walker CS Function and expression of two calcitonin gene-related peptide receptors within the sensory trigeminal system. In: 17th Congress of the International Headache Society, Valencia, 2015.
71.
Doods H, Hallermayer G, Wu D, et al. Pharmacological profile of BIBN-4096BS, the first selective small molecule CGRP antagonist. Br J Pharmacol. 2000;129:420–3.PubMedPubMedCentralCrossRef
72.
Chiba T, Yamaguchi A, Yamatani T, et al. Calcitonin gene-related peptide receptor antagonist human CGRP-(8-37). Am J Physiol. 1989;256:E331–5.PubMed
73.
Mallee JJ, Salvatore CA, LeBourdelles B, et al. Receptor activity-modifying protein 1 determines the species selectivity of non-peptide CGRP receptor antagonists. J Biol Chem. 2002;277:14294–8.PubMedCrossRef
74.
Olesen J, Diener HC, Husstedt IW, et al. Calcitonin gene-related peptide receptor antagonist BIBN 4096 BS for the acute treatment of migraine. N Engl J Med. 2004;350:1104–10.PubMedCrossRef
75.
Bigal ME, Walter S. Monoclonal antibodies for migraine: preventing calcitonin gene-related peptide activity. CNS Drugs. 2014;28:389–99.PubMedCrossRef
76.
Williams TM, Stump CA, Nguyen DN, et al. Non-peptide calcitonin gene-related peptide receptor antagonists from a benzodiazepinone lead. Bioorg Med Chem Lett. 2006;16:2595–8.PubMedCrossRef
77.
Burgey CS, Paone DV, Shaw AW, et al. Synthesis of the (3R,6S)-3-amino-6-(2,3-difluorophenyl)azepan-2-one of telcagepant (MK-0974), a calcitonin gene-related peptide receptor antagonist for the treatment of migraine headache. Org Lett. 2008;10:3235–8.PubMedCrossRef
78.
Ho TW, Olesen J, Dodick DW, Kost J, Lines C, Ferrari MD. Antimigraine efficacy of telcagepant based on patient’s historical triptan response. Headache. 2011;51:64–72.PubMedCrossRef
79.
Ho TW, Mannix LK, Fan X, et al. Randomized controlled trial of an oral CGRP receptor antagonist, MK-0974, in acute treatment of migraine. Neurology. 2008;70:1304–12.PubMedCrossRef
80.
Ho TW, Ferrari MD, Dodick DW, et al. Efficacy and tolerability of MK-0974 (telcagepant), a new oral antagonist of calcitonin gene-related peptide receptor, compared with zolmitriptan for acute migraine: a randomised, placebo-controlled, parallel-treatment trial. Lancet. 2008;372:2115–23.PubMedCrossRef
81.
Ho TW, Ho AP, Chaitman BR, et al. Randomized, controlled study of telcagepant in patients with migraine and coronary artery disease. Headache. 2012;52:224–35.PubMedCrossRef
82.
Tepper SJ, Cleves C. Telcagepant, a calcitonin gene-related peptide antagonist for the treatment of migraine. Curr Opin Investig Drugs. 2009;10:711–20.PubMed
83.
Ho TW, Connor KM, Zhang Y, et al. Randomized controlled trial of the CGRP receptor antagonist telcagepant for migraine prevention. Neurology. 2014;83:958–66.PubMedCrossRef
84.
Yao G, Yu T, Han X, Mao X, Li B. Therapeutic effects and safety of olcegepant and telcagepant for migraine: A meta-analysis. Neural Regen Res. 2013;8:938–47.PubMedPubMedCentral
85.
Silberstein SD. Emerging target-based paradigms to prevent and treat migraine. Clin Pharm Ther. 2012;93:78–85.CrossRef
86.
Diener HC, Barbanti P, Dahlof C, Reuter U, Habeck J, Podhorna J. BI 44370 TA, an oral CGRP antagonist for the treatment of acute migraine attacks: results from a phase II study. Cephalalgia. 2011;31:573–84.PubMedCrossRef
87.
Coloma MJ, Lee HJ, Kurihara A, et al. Transport across the primate blood-brain barrier of a genetically engineered chimeric monoclonal antibody to the human insulin receptor. Pharm Res. 2000;17:266–74.PubMedCrossRef
88.
Silberstein SD. Therapeutic monoclonal antibodies for migraine. US Neurol 2015;11 (ePub).
89.
Foltz IN, Karow M, Wasserman SM. Evolution and emergence of therapeutic monoclonal antibodies: what cardiologists need to know. Circulation. 2013;127:2222–30.PubMedCrossRef
90.
91.
Dodick DW, Goadsby PJ, Spierings EL, Scherer JC, Sweeney SP, Grayzel DS. Safety and efficacy of LY2951742, a monoclonal antibody to calcitonin gene-related peptide, for the prevention of migraine: a phase 2, randomised, double-blind, placebo-controlled study. Lancet Neurol. 2014;13:885–92.PubMedCrossRef
92.
Goadsby PJ, Dodick DW, Silberstein SD, Lipton RB, Olesen J, Ashina M, Wilks K, Kudrow D, Kroll R, Kohrman B, Bargar R, Hirman J, and Smith J Randomized, double-blind, placebo-controlled trial of ALD403, an anti-CGRP antibody in the prevention of frequent episodic migraine. In: 17th Congress of the International Headache Society, Valencia, 2015.
93.
Dodick DW, Goadsby PJ, Silberstein SD, et al. Safety and efficacy of ALD403, an antibody to calcitonin gene-related peptide, for the prevention of frequent episodic migraine: a randomised, double-blind, placebo-controlled, exploratory phase 2 trial. Lancet Neurol. 2014;13:1100–7.PubMedCrossRef
94.
Bigal ME, Edvinsson L, Rapoport A, Lipton R, Spierings E, Diener HC, Ma M, Hudson D, and Silberstein S A multicenter, randomized, double-blind, double-dummy, placebo-controlled, multi-dose study comparing the efficacy and safety of subcutaneous TEV-48125 with placebo for the preventive treatment of chronic migraine. In: 17th Congress of the International Headache Society, Valencia, 2015.
95.
Lenz R, Silberstein S, Dodick D, Reuter U, Ashina M, Saper J, Cady R, Chon Y, Dietrich J, and Sun H Results of a randomized, double-blind, placebo-controlled, phase 2 study to evaluate the efficacy and safety of AMG 334 for the prevention of episodic migraine. In: 17th Congress of the International Headache Society, Valencia, 2015.
96.
Bigal ME, Ferrari M, Silberstein SD, Lipton RB, Goadsby PJ. Migraine in the triptan era: lessons from epidemiology, pathophysiology, and clinical science. Headache. 2009;49(Suppl 1):S21–33.PubMedCrossRef
97.
Walter S, Alibhoy A, Escandon R, Bigal ME. Evaluation of cardiovascular parameters in cynomolgus monkeys following IV administration of LBR-101, a monoclonal antibody against calcitonin gene-related peptide. MAbs. 2014;6:871–8.PubMedPubMedCentralCrossRef
98.
Bigal ME, Walter S, Bronson M, Alibhoy A, Escandon R. Cardiovascular and hemodynamic parameters in women following prolonged CGRP inhibition using LBR-101, a monoclonal antibody against CGRP. Cephalalgia. 2014;34(12):968–76.PubMedCrossRef
99.
Zeller J, Poulsen KT, Sutton JE, et al. CGRP function-blocking antibodies inhibit neurogenic vasodilatation without affecting heart rate or arterial blood pressure in the rat. Br J Pharmacol. 2008;155:1093–103.PubMedPubMedCentralCrossRef
100.
Bigal ME, Escandon R, Bronson M, et al. Safety and tolerability of LBR-101, a humanized monoclonal antibody that blocks the binding of CGRP to its receptor: results of the Phase 1 program. Cephalalgia. 2013;34:483–92.PubMedCrossRef
101.
Feuerstein G, Willette R, Aiyar N. Clinical perspectives of calcitonin gene related peptide pharmacology. Can J Physiol Pharmacol. 1995;73:1070–4.PubMedCrossRef
102.
Sur C, Hargreaves R, Bell I, et al. CSF levels and binding pattern of novel CGRP receptor antagonists in rhesus monkey and human central nervous system: toward the development of a PET tracer. Cephalalgia. 2009;29:136–7.
103.
Hostetler ED, Joshi AD, Sanabria-Bohorquez S, et al. In vivo quantification of calcitonin gene-related peptide receptor occupancy by telcagepant in rhesus monkey and human brain using the positron emission tomography tracer [11C]MK-4232. J Pharmacol Exp Ther. 2013;347:478–86.PubMedCrossRef
104.
Vermeersch SG, deHoon J, deSaint-Hubert B, et al. PET imaging in healthy subjects and migraineurs suggests CGRP receptor antagonists do not have to act centrally to achieve clinical efficacy. J Headache and Pain. 2013;14:224 (Abstract).CrossRef
105.
Edvinsson L. CGRP receptor antagonists and antibodies against CGRP and its receptor in migraine treatment. Br J Clin Pharmacol. doi:10.​1111/​bcp.​12618 [Epub ahead of print] PubMed
106.
Kaube H, Hoskin KL, Goadsby PJ. Inhibition by sumatriptan of central trigeminal neurones only after blood-brain barrier disruption. Br J Pharmacol. 1993;109:788–92.PubMedPubMedCentralCrossRef
107.
108.
Zhang X, Levy D, Noseda R, Kainz V, Jakubowski M, Burstein R. Activation of meningeal nociceptors by cortical spreading depression: implications for migraine with aura. J Neurosci. 2010;30:8807–14.PubMedPubMedCentralCrossRef
109.
Zhang X, Levy D, Kainz V, Noseda R, Jakubowski M, Burstein R. Activation of central trigeminovascular neurons by cortical spreading depression. Ann Neurol. 2011;69:855–65.PubMedPubMedCentralCrossRef
110.
Tozzi A, de Iure A, Di Filippo M, et al. Critical role of calcitonin gene-related peptide receptors in cortical spreading depression. Proc Natl Acad Sci USA. 2012;109:18985–90.PubMedPubMedCentralCrossRef
111.
Piper RD, Edvinsson L, Ekman R, Lambert GA. Cortical spreading depression does not result in the release of calcitonin gene-related peptide into the external jugular vein of the cat: relevance to human migraine. Cephalalgia. 1993;13:180–3.PubMedCrossRef
112.
De FM, Ossipov MH, Wang R, et al. Triptan-induced latent sensitization: a possible basis for medication overuse headache. Ann Neurol. 2010;67:325–37.
113.
De FM, Porreca F. Opiate-induced persistent pronociceptive trigeminal neural adaptations: potential relevance to opiate-induced medication overuse headache. Cephalalgia. 2009;29:1277–84.CrossRef
114.
Michot B, Bourgoin S, Viguier F, Hamon M, Kayser V. Differential effects of calcitonin gene-related peptide receptor blockade by olcegepant on mechanical allodynia induced by ligation of the infraorbital nerve vs the sciatic nerve in the rat. Pain. 2012;153:1939–48.PubMedCrossRef
115.
Drummond PD. A quantitative assessment of photophobia in migraine and tension headache. Headache. 1986;26:465–9.PubMedCrossRef
116.
117.
118.
Maleki N, Becerra L, Upadhyay J, Burstein R, Borsook D. Direct optic nerve pulvinar connections defined by diffusion MR tractography in humans: implications for photophobia. Hum Brain Mapp. 2012;33:75–88.PubMedPubMedCentralCrossRef
Metadaten
Titel
Targeting CGRP: A New Era for Migraine Treatment
verfasst von
Stephanie Wrobel Goldberg
Stephen David Silberstein
Publikationsdatum
01.06.2015
Verlag
Springer International Publishing
Erschienen in
CNS Drugs / Ausgabe 6/2015
Print ISSN: 1172-7047
Elektronische ISSN: 1179-1934
DOI
https://doi.org/10.1007/s40263-015-0253-z

Weitere Artikel der Ausgabe 6/2015

CNS Drugs 6/2015 Zur Ausgabe

Leading Article

Developing Medications Targeting Glutamatergic Dysfunction in Autism: Progress to Date

Review Article

Alzheimer’s Disease: Lessons Learned from Amyloidocentric Clinical Trials

Current Opinion

Defining the Role of the Monoamine Oxidase-B Inhibitors for Parkinson’s Disease

Review Article

Targeting Opioid-Induced Hyperalgesia in Clinical Treatment: Neurobiological Considerations

Adis Drug Evaluation

Oxycodone/Naloxone PR: A Review in Severe Refractory Restless Legs Syndrome

Original Research Article

Platform Therapy Compared with Natalizumab for Multiple Sclerosis: Relapse Rates and Time to Relapse Among Propensity Score-Matched US Patients

Leitlinien kompakt für die Neurologie

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Kostenlos registrieren

Neu im Fachgebiet Neurologie

Sind Frauen die fähigeren Ärzte?

30.04.2024 Gendermedizin Nachrichten

Patienten, die von Ärztinnen behandelt werden, dürfen offenbar auf bessere Therapieergebnisse hoffen als Patienten von Ärzten. Besonders gilt das offenbar für weibliche Kranke, wie eine Studie zeigt.

Akuter Schwindel: Wann lohnt sich eine MRT?

28.04.2024 Schwindel Nachrichten

Akuter Schwindel stellt oft eine diagnostische Herausforderung dar. Wie nützlich dabei eine MRT ist, hat eine Studie aus Finnland untersucht. Immerhin einer von sechs Patienten wurde mit akutem ischämischem Schlaganfall diagnostiziert.

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

25.04.2024 Hypotonie Nachrichten

Wenn unter einer medikamentösen Hochdrucktherapie der diastolische Blutdruck in den Keller geht, steigt das Risiko für schwere kardiovaskuläre Ereignisse: Darauf deutet eine Sekundäranalyse der SPRINT-Studie hin.

Frühe Alzheimertherapie lohnt sich

25.04.2024 AAN-Jahrestagung 2024 Nachrichten

Ist die Tau-Last noch gering, scheint der Vorteil von Lecanemab besonders groß zu sein. Und beginnen Erkrankte verzögert mit der Behandlung, erreichen sie nicht mehr die kognitive Leistung wie bei einem früheren Start. Darauf deuten neue Analysen der Phase-3-Studie Clarity AD.

Update Neurologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen
Bildnachweise